Lyell Immunopharma (NasdaqGS:LYEL) Earnings Call Presentation

LYL273 Acquisition and Pipeline - Lyell Immunopharma strengthens its CAR T-cell pipeline with LYL273, a novel GCC-targeted product candidate for metastatic colorectal cancer (mCRC)[1] - LYL273 targets GCC, which is expressed on over 95% of mCRC and a majority of pancreatic cancers[12] - The acquisition includes an upfront payment of $40 million and 1.9 million shares, with potential for additional clinical, regulatory, and commercial milestones plus tiered royalties[12] - Lyell's LyFE manufacturing facility has a capacity for >1,200 doses/year at full capacity[75] Clinical Trial Data and Efficacy of LYL273 - In a U S Phase 1 clinical trial, LYL273 showed a 67% overall response rate at Dose Level 2 in patients with refractory mCRC[12, 32] - The disease control rate was 83% at the highest dose of LYL273 evaluated in the U S Phase 1 clinical trial[12] - In a Chinese study, at Dose Level 2, median OS was 25 months (95% CI, 13 4 to 26 1), median PFS was 6 0 months (95% CI, 3 0 to NA)[24] - One patient in the U S trial achieved a pathological complete response at autopsy[32, 42] Market and Future Milestones - The worldwide projected net sales for colorectal cancer are a $6+ billion market[13, 16] - Lyell anticipates the next data update for LYL273 in the first half of 2026[57, 81] - The company's cash runway extends into 2027, through multiple clinical milestones[81, 85]